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Abstract
Background: Obesity	accompanied	by	excess	ectopic	fat	storage	has	been	postulated	
as	a	risk	factor	for	severe	disease	in	people	with	SARS-CoV-2	through	the	stimulation	
of	inflammation,	functional	immunologic	deficit	and	a	pro-thrombotic	disseminated	
intravascular coagulation with associated high rates of venous thromboembolism.
Methods: Observational	 studies	 in	 COVID-19	 patients	 reporting	 data	 on	 raised	
body	mass	index	at	admission	and	associated	clinical	outcomes	were	identified	from	
MEDLINE,	Embase,	Web	of	Science	and	the	Cochrane	Library	up	to	16	May	2020.	
Mean	differences	and	relative	risks	(RR)	with	95%	confidence	intervals	(CIs)	were	ag-
gregated using random effects models.
Results: Eight	retrospective	cohort	studies	and	one	cohort	prospective	cohort	study	
with	data	on	of	4,920	patients	with	COVID-19	were	eligible.	Comparing	BMI	≥	25	vs	
<25	kg/m2,	the	RRs	(95%	CIs)	of	severe	illness	and	mortality	were	2.35	(1.43-3.86)	
and	3.52	(1.32-9.42),	respectively.	In	a	pooled	analysis	of	three	studies,	the	RR	(95%	
CI)	of	severe	illness	comparing	BMI	>	35	vs	<25	kg/m2	was	7.04	(2.72-18.20).	High	
levels	of	statistical	heterogeneity	were	partly	explained	by	age;	BMI	≥	25	kg/m2 was 
associated	with	an	 increased	risk	of	severe	 illness	 in	older	age	groups	 (≥60	years),	
whereas the association was weaker in younger age groups (<60	years).
Conclusions: Excess	adiposity	is	a	risk	factor	for	severe	disease	and	mortality	in	peo-
ple	with	SARS-CoV-2	infection.	This	was	particularly	pronounced	in	people	60	and	
older.	The	 increased	risk	of	worse	outcomes	from	SARS-CoV-2	 infection	 in	people	
with	excess	adiposity	should	be	taken	into	account	when	considering	individual	and	
population risks and when deciding on which groups to target for public health mes-
saging on prevention and detection measures.
Systematic review registration:	PROSPERO	2020:	CRD42020179783.
K E Y W O R D S
mortality,	obesity,	SARS-CoV-2,	severe	disease
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1  | BACKGROUND
The	severe	acute	respiratory	syndrome	coronavirus	2	 (SARS-CoV-2),	
initially	reported	in	November	2019	in	Wuhan,	China,	has	now	claimed	
over 300 000 lives globally1 and devastated the global economy. It 
continues to severely affect the social fabrics of most counties. The un-
precedented projected mortality and economic devastation caused by 
the virus has led to global research efforts to identify people at great-
est risk of developing critical illness and dying. Chen et al identified 
older	age,	male	gender	and	comorbidities	such	as	hypertension,	diabe-
tes,	cardiovascular	disease	and	chronic	lung	disease	as	risk	factors	for	
severe	disease	when	they	compared	the	characteristics	of	113	(14.4%)	
patients who had died of the disease with those of 161 patients who 
recovered.2 Recent studies have increasingly described obesity as an 
associating factor for people at an increased risk of severe disease.3-6 
The	risk	of	many	chronic	diseases	such	as	cardiovascular	disease,	can-
cer,	diabetes	and	the	mortality	 in	 individuals	with	these	diseases	 in-
creases significantly in people with obesity or overweight.7 With the 
World	Health	Organization	estimating	that	more	than	1.9	billion	adults	
worldwide	have	overweight	or	obesity,8 any causal relationship or as-
sociation	between	obesity	and	severe	disease	from	SARS-CoV-2	has	
the potential to claim even more lives globally.
There may be pathophysiological mechanisms for worse out-
comes	 in	 people	with	 excess	 adipose	 tissues.9	 Excess	 adipose	 tis-
sue	leads	to	local	insulin	resistance	and	may	stimulate	inflammation,	
functional	 immunologic	deficit	 and	a	pro-thrombotic	disseminated	
intravascular coagulation with associated high rates of venous 
thromboembolism.10,11
Conversely,	 the	 phenomenon	 of	 the	 ‘obesity	 paradox’	 has	
emerged from epidemiological data in recent years to suggest coun-
terintuitively that people with overweight and obesity may have a 
better	prognosis	 than	 those	with	BMI	values	 in	 the	normal	 range.	
This phenomenon has thus far been described in patients with hy-
pertension,	heart	failure,	coronary	artery	disease,	peripheral	artery	
disease and other cardiovascular and noncardiovascular condi-
tions.12,13 The phenomenon seems more convincing in older popu-
lations where weight and muscle mass start to decline at advanced 
age.	Sarcopenia	 is	 a	major	 contributor	 to	age-related	 frailty.14 It is 
therefore	possible	 that	people	with	overweight	and	obesity,	espe-
cially	in	older	populations,	could	have	less	severe	disease	and	mor-
tality compared to individuals with normal weight.
In	this	context,	whether	obesity	has	better	or	worse	impact	on	
the	 occurrence	 of	 severe	 disease	 or	 death	 in	 people	 with	 SARS-
CoV-2	is	uncertain.	A	recent	systematic	review	on	this	topic	identi-
fied only three studies and concluded that obesity is an independent 
risk	and	prognostic	factor	for	SARS-CoV-2.	The	review	was	limited	
by	the	small	number	of	 included	studies,	the	absence	of	some	key	
data and the lack of quantitative synthesis.15 In order to attempt to 
quantify the relationship between raised body weight and severe 
outcomes	 from	COVID-19,	we	conducted	a	systematic	 review	and	
meta-analysis	to	determine	whether	people	with	overweight	or	obe-
sity	 and	 with	 SARS-CoV-2	 have	 different	 outcomes	 compared	 to	
those within normal weight thresholds.
2  | METHODS
2.1 | Data sources and search strategy
This	 review	 was	 conducted	 and	 reported	 based	 on	 PRISMA	 and	
MOOSE	 guidelines16,17	 (Appendices	 S1	 and	 S2)	 and	 in	 accord-
ance	with	 a	 protocol	which	 has	 been	 registered	with	 PROSPERO,	
(CRD42020179783).	 We	 searched	 MEDLINE,	 Embase,	 Web	 of	
Science	and	The	Cochrane	Library	from	inception	to	16	May	2020	
for studies reporting on relationships between overweight and 
obesity	 and	 the	 clinical	 outcomes	 in	patients	with	COVID-19.	The	
computer-based	 searches	 combined	 free	 and	MeSH	 search	 terms	
and	key	words	related	to	the	exposures	(such	as	‘Body	Mass	Index’,	
‘BMI’	 ‘Body	 Weight’	 ‘Obesity’.)	 and	 population	 (eg	 ‘COVID-19’,	
‘SARS-CoV-2’)	in	humans.	The	search	strategy	was	limited	to	English	
language given the potential for duplicate reporting of same study 
participants.18	The	full	search	strategy	is	reported	in	Appendix	S3.	
The titles and abstracts of retrieved citations were initially screened 
by	one	reviewer	 (SS)	 for	potential	eligible	studies	based	on	the	 in-
clusion	criteria.	Full	 texts	of	potential	eligible	abstracts	were	 then	
acquired	for	the	detailed	evaluation	by	2	reviewers	(SS	and	SKK).	To	
potentially	identify	articles	missed	by	the	search	strategy,	reference	
lists of relevant articles were manually scanned.
2.2 | Study selection and eligibility criteria
The protocol was designed to include all observational studies 
(prospective	 cohort,	 retrospective,	 nested	 case-control	 and	 case-
control),	 clinical	 studies,	 nonrandomized	 controlled	 trials	 (RCTs)	
and RCTs reporting a relationship between obesity and the clinical 
outcomes	in	patients	with	COVID-19.	Article	types	such	as	opinion	
pieces,	consensus	reports,	single	case	studies	and	narrative	reviews	
were	 excluded.	 Outcomes	 evaluated	 included	 severe	 disease	 (de-
fined	as	intensive	care	unit	(ICU)	care,	SpO2 <	90%,	requiring	sup-
plemental O2)	 and	 mortality.	 No	 limits	 were	 placed	 on	 the	 study	
follow-up	duration.
2.3 | Data extraction and quality assessment
Using	a	predesigned	data	extraction	 form	which	had	been	piloted	
by	one	 reviewer	 (SKK),	data	on	patient	characteristics	 (eg	average	
age,	sex,	percentage	of	males,	location);	study	design;	BMI	(means,	
medians,	standard	deviations	 [SDs]	and	 interquartile	ranges	 [IQRs]	
in	each	outcome	group);	outcomes;	and	risk	estimates	where	avail-
able	(relative	risks	[RR]	with	95%	confidence	intervals	[CIs],	hazard	
ratios	 [HRs]	 and	 odds	 ratios	 [ORs])	were	 extracted.	 The	 nine-star	
Newcastle-Ottawa	Scale	(NOS),19 a validated tool for assessing the 
quality	of	nonrandomized	studies,	was	used	to	assess	the	methodo-
logical quality of the studies. This tool measures the quality of evi-
dence from a score of zero to nine (higher scores =	better),	based	
on	 three	predefined	domains	 including	 the	 following:	 (a)	 selection	
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of	participants;	(b)	comparability;	and	(c)	ascertainment	of	outcomes	
of interest.
2.4 | Statistical analysis
Mean	differences	(95%	CIs)	for	comparing	mean	levels	of	body	mass	
index	(BMI)	across	outcomes	and	RRs	(95%	CIs)	for	associations	be-
tween	BMI	categories	and	outcomes	were	used	as	summary	meas-
ures	across	studies.	The	reported	HRs	were	assumed	to	approximate	
the	same	measure	of	RR.	Multivariable-adjusted	risk	estimates	were	
used	for	pooling	if	available,	otherwise	crude	RRs	were	used	as	re-
ported.	For	data	reported	as	medians,	standard	errors,	 ranges	and	
95%	confidence	intervals	(CIs),	means	and	standard	deviations	were	
estimated using methods as described by Hozo and colleagues.20 
Due	 to	 the	 different	 cut-offs	 used	 for	 BMI	 by	 the	 included	 stud-
ies,	we	employed	the	risk	comparison:	≥25	vs	<25	kg/m2,	to	ensure	
consistency in the pooling approach and enhance comparability 
and interpretation of findings. Subsidiary analyses employed the 
cut-off	>	35	vs	<25	kg/m2.	 Similarly,	 as	 there	was	heterogeneous	
reporting	of	outcomes,	we	categorized	them	into	two	main	groups	
for	consistency:	(a)	severe	illness	(requiring	intensive	care	unit	(ICU)	
care,	SpO2 <	90%,	and	requiring	supplemental	O2)	and	(b)	mortality.	
Random effects models using the inverse variance weighted method 
(DerSimonian	and	Laird)	were	used	to	combine	RRs	to	minimize	the	
effect of heterogeneity. Heterogeneity was assessed and quantified 
using the Cochrane χ2 statistic and the I2 statistic.21 Prespecified 
study-level	 characteristics	 such	 as	 geographical	 location,	 average	
age	at	baseline	and	study	quality	were	explored	as	sources	of	het-
erogeneity,	 using	 stratified	 analysis	 and	 random	 effects	 meta-re-
gression.22 We assessed for evidence of publication bias using visual 
inspection	of	Begg's	funnel	plots	and	Egger's	regression	symmetry	
tests.	STATA	release	MP	16	(StataCorp	LP)	was	used	for	all	statistical	
analyses.
3  | RESULTS
3.1 | Study identification and selection
The flow of studies through the review process is presented in 
Figure	1.	A	total	of	17	articles	were	identified	from	the	search	of	da-
tabases and another three from manual scanning of reference lists of 
relevant	studies.	After	initial	screening	based	on	titles	and	abstracts,	
nine	articles	remained	for	full-text	evaluation.	Eleven	articles	were	
excluded	because	(a)	the	exposure	was	not	relevant	(n	=	3),	(b)	out-
come was not relevant (n =	1),	(c)	duplicate	(n	=	1	and	(d)	inappro-
priate	article	types	such	as	opinion	pieces,	consensus	reports	single	
case studies and narrative reviews (n =	6).
3.2 | Study characteristics and quality
All	nine	studies	comprised	of	observational	cohorts	 (8	retrospec-
tive	 and	 1	 prospective)	 and	 comprised	 of	 4920	 patients	 with	
COVID-19,	 of	 which	 841	 developed	 severe	 illness	 and	 136	 died	
F I G U R E  1   Selection of studies 
included	in	the	meta-analysis
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(Table	1).	 Four	 studies	were	based	 in	Asia	 (China	 and	Singapore)	
(n =	549),	three	from	Europe	(France	and	Italy)	(n	=	653)	and	two	
from	North	America	(USA)	(n	=	3718).	The	average	age	at	baseline	
ranged	from	approximately	43	to	64	years,	with	a	weighted	mean	
(SD)	of	56.8	(8.3)	years.	All	studies	enrolled	both	male	and	female	
patients. The overall NOS methodological quality scores of studies 
ranged from 4 to 7.
3.3 | BMI and risk for severe illness and mortality
Comparing	BMI	≥	25	vs	<25	kg/m2,	the	RRs	(95%	CIs)	of	severe	ill-
ness (n =	6	studies)	and	mortality	 (n	=	4	studies)	were	2.35	(1.43-
3.86; I2 =	71%;	95%	CI	33,	88%;	P for heterogeneity =	.004)	and	3.52	
(1.32-9.42;	I2 =	66%;	95%	CI	0,	88%;	P for heterogeneity =	.03),	re-
spectively	(Figure	2).	In	pooled	analysis	of	three	studies,	the	RR	(95%	
CI)	 of	 severe	 illness	 comparing	BMI	>	 35	 vs	<25	 kg/m2 was 7.04 
(2.72-18.20;	 I2 =	29%;	95%	CI	0,	74%;	P for heterogeneity =	0.24)	
(Figure	3).
Figure	4	shows	BMI	 levels	 in	patients	with	severe	 illness	com-
pared	with	their	controls	(those	without	severe	illness).	Pooled	anal-
ysis	of	 four	studies	each	showed	significantly	higher	BMI	 levels	 in	
COVID-19	patients	with	severe	illness	compared	to	patients	without	
severe	illness:	mean	difference	(95%	CI)	of	3.08	kg/m2	 (2.09,	4.08;	
P < .01; I2 =	87%;	95%	CI	69,	95%;	P for heterogeneity <	.01).
3.4 | Subgroup analyses and observed 
heterogeneity
The substantial heterogeneity between the contributing stud-
ies	 reporting	on	 the	association	between	BMI	≥	25	vs	<25	kg/m2 
and	 risk	 of	 severe	 illness	may	be	 partly	 explained	by	 age	 (P-value	
for	 meta-regression	<	 .001)	 and	 study	 quality	 (P-value	 for	 meta-
regression =	 .02)	(Figure	5).	In	subgroup	analyses,	BMI	≥	25	kg/m2 
was associated with a statistically significant increased risk of severe 
illness	in	older	age	groups	(≥60	years);	the	point	estimate	was	lower	
and the difference was no longer statistically significant in younger 
age groups (<60	years).	In	a	second	subgroup	analysis,	BMI	≥	25	kg/
m2 was associated with statistically significant increased risk of se-
vere	 illness	 in	higher	quality	studies	 (NOS	≥	7),	whereas	 the	point	
estimate was lower and no longer statistically significant in studies 
with a lower quality score (NOS <	7)	(Figure	5).	Given	the	reduced	
heterogeneity	in	the	comparison	of	BMI	>	35	kg/m2 vs <25	kg/m2 
and	the	markedly	higher	point	estimate	in	this	comparison,	it	is	also	
likely	that	difference	in	BMI	ranges	and	thresholds	between	studies	
contributed to the high levels of statistical heterogeneity in both the 
analyses	comparing	BMI	≥	25	vs	<25	kg/m2.
The reasons for the observed heterogeneity in our analysis 
comparing	 BMI	 levels	 in	 people	with	 severe	 illness	 compared	 to	
those	without	is	unclear;	due	to	the	small	number	of	studies,	sub-
group	analyses	were	not	appropriate.	However,	despite	high	 lev-
els	of	statistical	heterogeneity,	all	studies	included	in	this	analysis	
found	statistically	 significant	 increases	 in	BMI	 in	people	with	se-
vere disease; the direction of effect was consistent and differences 
in the magnitude of effect drove the statistical heterogeneity in 
this case.
4  | DISCUSSION
Using	 a	 systematic	 review	and	meta-analytical	 approach,	we	have	
summarized	the	available	studies	of	SARS-CoV-2	patients	that	have	
assessed	relationships	between	raised	BMI	and	the	adverse	clinical	
outcomes of severe illness and mortality. Our main finding of peo-
ple	 with	 increased	 BMI	 with	 SARS-CoV-2	 being	 at	 increased	 risk	
of severe disease and death reinforces the findings from a smaller 
review15 indicating that obesity is an important risk factor for se-
vere	SARS-CoV-2	disease.	In	addition,	several	other	opinion	pieces,	
editorials and reviews9,23-25 have recently suggested that after ad-
justing	 for	 comorbidities,	 obesity	 is	 a	 significant	 factor	 associated	
with	in-hospital	death	in	SARS-CoV-2.	Severe	obesity	has	now	been	
recognized	by	the	Centers	for	Disease	Control	and	Prevention	(CDC)	
as a common clinical risk factor for worse outcomes and higher mor-
tality	 in	 people	 with	 SARS-CoV-2.26 These findings in relation to 
SARS-Cov-2	and	excess	 adiposity	 are	 consistent	with	 associations	
seen	 in	other	 infectious	diseases,	 including	 the	H1N1	pandemic.27 
People with overweight or obesity are generally more likely to have 
more	severe	infections,	decreased	responses	to	treatments	and	an	
increased risk of death.27
We	have	shown	that	people	with	higher	BMI	have	an	increased	
risk	of	severe	disease	in	older	age	groups	(≥60	years);	the	association	
was	less	clear	in	younger	people.	In	a	recent	analysis	of	265	patients	
with	COVID-19,	Kass	et	al28 described a significant inverse correla-
tion	between	age	and	BMI,	 in	which	younger	 individuals	admitted	
to	hospital	were	more	likely	to	be	obese.	The	authors	suggest	that,	
on	this	basis,	public	messaging	to	younger	adults	be	clear	that	even	
at	younger	ages,	they	are	still	vulnerable	to	COVID-19.	Though	our	
data	did	not	find	the	same	pattern	as	Kass	et	al,	we	do	not	disagree	
with this messaging. The average age at baseline in our population 
ranged	from	approximately	43	to	64	years,	which	is	relatively	young.	
Despite	this	relatively	young	population,	17%	of	our	population	had	
severe disease or death.
4.1 | Possible mechanisms explaining the link 
between raised body weight and worse outcomes 
from COVID-19
Several	mechanisms	could	explain	why	raised	body	weight	predis-
poses	 patients	 with	 SARS-CoV-2	 to	 severe	 disease.	 First,	 raised	
body weight increases mechanical pressure on chest and abdomen 
causing	 diaphragmatic	 embarrassment,	 thus	 restricting	 pulmonary	
function,	especially	when	 lying	supine.	This	causes	a	decrease	ex-
piratory	reserve	volume,	functional	capacity	and	respiratory	system	
compliance.24
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Second,	 obesity	 is	 associated	with	 type	2	diabetes	 and	hyper-
tension,	both	of	which	constitute	important	risk	factors	for	cardio-
vascular	disease	and	are	very	prevalent	 in	SARS-CoV-2	patients.29 
Similarly,	obesity	is	one	of	the	leading	risk	factors	for	atrial	fibrilla-
tion	and	this	is	a	common	condition	present	in	severe	forms	SARS-
CoV-2.30	Given	limitations	in	our	data,	we	were	unable	to	ascertain	
the	 extent	 to	which	 pre-existing	 conditions	 contribute	 to	 the	 ob-
served	association	between	raised	BMI	and	worse	outcomes	from	
COVID-19.
Thirdly,	obese	patients	have	excess	ectopic	visceral	fat,	which	
correlates with a cluster of metabolic abnormalities.31	Visceral	fat	
represents a metabolically active organ and has been strongly re-
lated to insulin sensitivity32,33	 and	CVD.	 Visceral	 fat	 adipocytes	
are	 insulin-resistant	 cells	 within	 a	 network	 of	 blood	 capillaries	
and infiltrating inflammatory cells.34 Inflammatory cells within the 
visceral fat may play a role in adipocyte behaviour as a source of 
hormones	and	cytokines,	called	adipokines,	with	proinflammatory	
and proatherogenic action. Obesity is therefore proinflammatory. 
Thus,	 in	 a	 patient	 with	 an	 already	 underlying	 proinflammatory	
state,	the	exposure	to	a	viral	infection	in	which	early	reports	sug-
gest that a cytokine storm syndrome35	occurs,	associated	with	an	
overproduction of immune cells and proinflammatory cytokines 
(eg	IL-6,	IL-10	and	TNF-α),36 is likely to predispose to more severe 
disease.
Fourthly,	 SARS-CoV-2	 binds	 with	 angiotensin-converting	
enzyme	2	 (ACE2)	 receptors	 on	 the	 cell	 surfaces.	 Excess	 visceral	
fat is linked to insulin resistance and a heightened activity of al-
dosterone	 system	 (RAAS),	which	 is	 linked	with	worse	 outcomes	
in	COVID-19.37	Even	though	the	 lung	 is	 the	main	entry	point	 for	
COVID-19,	it	has	been	noted	that	there	is	an	increased	ACE2	ex-
pression	in	adipose	tissue,	thus	making	it	a	more	vulnerable	target	
for	COVID-19	infection.38	The	presence	of	ACE2	may	enable	the	
entry	of	SARS-CoV-2	into	adipocytes,	which	makes	adipose	tissue	
an important viral reservoir for greater viral shedding suggest-
ing	potential	 for	 great	 viral	 exposure,38 through spread to other 
organs.39
Finally,	 obesity	 enhances	 thrombosis,40,41 and this increases 
with the severity of obesity.42 The mechanistic pathway impli-
cated	 in	obesity-related	hypercoagulability	 includes	 the	actions	of	
adipocytokines,	 coagulation	 factors	 hyperactivity	 and	 increased	
inflammation	 (tumour	 necrosis	 factor	 [TNF],	 interleukin-6	 [IL-6])	
among others.43	 COVID-19	 has	 been	 noted	 to	 be	 associated	with	
F I G U R E  2  Associations	of	BMI	≥	25	vs	<25	kg/m2	with	risk	of	severe	illness	and	mortality	in	COVID-19	patients.	BMI,	body	mass	index;	
CI,	confidence	interval	(bars);	RR,	relative	risk
Author, year of 
publication
No. of 
cases
No. of 
patients
RR (95% CI)
Severe illness
Zheng, 2020
Kalligeros 2020
19
70
66
103
6.32 (1.16, 34.54)
3.95 (2.04, 7.65)
Simonnet 2020
Ong 2020
Lighter, 2020
Rottoli, 2020
85
43
431
110
124
91
3615
296
3.09 (1.42, 6.73)
1.15 (0.58, 2.29)
1.38 (1.05, 1.82)
3.16 (1.63, 6.13) 
Subtotal
Mortality
P 2020 17 112
  
2.35 (1.43, 3.86)
17 95 (4 35 74 16)eng  
Ong 2020
Giacomelli, 2020
Rottoli, 2020
4
48
67
91
233
296
.  . , .
0.40 (0.04, 4.04)
3.04 (1.42, 6.49)
3.11 (1.34, 7.25)
Subtotal 3.52 (1.32, 9.42)
1.01 .05 .25 5 15 45 150
RR (95% CI) BMI>25 vs <25
Favours BMI>25 Favours BMI<25
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pro-thrombotic	 disseminated	 intravascular	 coagulation	 and	 higher	
rates	 of	 venous	 thromboembolism,	 leading	 to	 worse	 outcomes.38 
Therefore,	increased	hypercoagulability	and	thrombosis	in	COVID-
19	patients	may	contribute	to	additive	effects	of	obesity	and	SARS-
CoV-2	infection.
4.2 | Strengths and limitations
Our analysis has several strengths. Our comprehensive search 
strategy yielded the highest number of published articles on this 
topic to date and evaluated the relationship of overweight and obe-
sity	on	adverse	outcomes	in	people	with	COVID-19.	We	were	able	
to transform reported risk estimates from majority of contribut-
ing studies to a consistent level to allow combination of estimates 
across	studies,	which	enhanced	interpretation	of	the	overall	find-
ings. Our subgroup analysis revealed that older age and higher 
quality	 studies	 explained	 some	 of	 the	 heterogeneity	 observed;	
different	 BMI	 thresholds	 and	 ranges	 across	 the	 included	 studies	
also likely contributed to the observed heterogeneity. We included 
studies	with	populations	from	a	wide	range	of	regions,	unlike	other	
reviews	 on	 COVID	 19,	 which	 tend	 to	 have	 patients	 over-repre-
sented	from	Asia.
Our	study	has	some	limitations,	most	of	which	relate	to	the	qual-
ity and reporting of the included studies as well as to differences 
between studies which contributed to statistical heterogeneity. The 
definitions	of	severe	illness	varied	across	the	studies;	hence,	the	use	
of	a	composite	measure	was	applied.	BMI	ranges	also	varied	across	
studies.	 Ethnicity,	 comorbid	 conditions	 and	 socio-economic	 status	
are	 linked	 to	 obesity	 and	 to	 worse	 COVID-19	 outcomes,	 but	 we	
were	unable	 to	 investigate	 these	 links	due	 to	 insufficient	data.	For	
the	same	reason,	the	role	of	comorbidities	has	not	been	accounted	
for	 in	 this	 analysis.	All	 of	 these	 factors	 could	be	 important	drivers	
of	 observed	 links	 between	 raised	 BMI	 and	 worse	 outcomes	 with	
COVID-19.	 In	addition,	sample	sizes	were	 limited;	hence,	there	was	
inadequate power to reliably evaluate the nature and magnitude of 
the	associations.	Finally,	there	is	a	potential	for	some	overlapping	to	
have	occurred	in	the	data,	though	this	is	unlikely	as	the	cases	were	all	
from	different	centres.	For	these	reasons,	though	the	data	are	consis-
tent	on	the	increased	risk	of	severe	disease	from	COVID-19	in	people	
with	raised	body	weight,	we	are	unable	to	explore	causality	or	to	pre-
cisely	quantify	risks.	Research	into	COVID-19	is	in	its	relative	infancy,	
and	as	more	data	emerge,	it	is	important	these	are	transparently	re-
ported	and	take	into	account	a	range	of	factors	related	to	COVID-19	
outcomes.	In	the	meantime,	the	policy	implications	of	the	observed	
link	between	raised	BMI	and	COVID-19	need	careful	consideration.
F I G U R E  3  Associations	of	BMI	>	35	vs	<25	kg/m2	with	risk	of	severe	illness	in	COVID-19	patients.	BMI,	body	mass	index;	CI,	confidence	
interval	(bars);	RR,	relative	risk
Author, year of 
publication
No. of 
cases
No. of 
patients
RR (95% CI)
Kalligeros 2020
Kalligeros 2020
29
41
103
103
9.99 (1.39, 71.69)
5.39 (1.13, 25.64)
Simonnet 2020
Lighter, 2020
30
431
124
3615
7.36 (1.63, 33.14)
2.56 (1.91, 3.43)
Overall 3.76 (1.97, 7.16)
1.25 5 15 45 100
52<IMBsruovaF53>IMBsruovaF
RR (95% CI) BMI>35 vs <25
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F I G U R E  4  BMI	levels	in	COVID-19	patients	with	or	without	severe	illness.	BMI,	body	mass	index;	CI,	confidence	interval	(bars);	RR,	
relative risk
Author, year of 
publication
Severe 
illness
Non-severe 
illness
Mean difference (kg/m2) 
(95% CI)
Peng, 2020 16 96 3.50 (2.93, 4.07)
Wu, 2020
Zheng, 2020
83
19
197
47
2.20 (1.61, 2.79)
2.00 (0.13, 3.87)
Overall
Simonet, 2020 85 39
3.08 (2.09, 4.08)
4.10 (3.54, 4.66)
Decreased in severe illness Increased in severe illness
0–2.5 2.5 5 7.5
         
Mean difference (kg/m2) 
F I G U R E  5  Associations	of	BMI	≥	25	vs	<25	kg/m2	with	risk	of	severe	illness	in	COVID-19	patients,	by	study-level	characteristics.	BMI,	
body	mass	index;	CI,	confidence	interval	(bars);	RR,	relative	risk
Location
Group No. with 
severe 
illness
No. of 
patients
RR (95% CI) p-value*
Asia
Western
62
396
157
4,138
2.24 (0.44, 11.45)
2.56 (1.40, 4.67)
.64
Age at baseline, yrs
≥ 60
< 60
265
493
523
3,772
3.41 (2.28, 5.09)
1.47 (0.90, 2.40)
<0.001
Study quality
≥ 7
< 7
174
584
293
4 002
3.73 (2.30, 6.05)
1 66 (0 98 2 79)
.02
 , .  . , .
1.25 .5 2.5 5 7.5 15
RR (95% CI) BMI>25 vs <25
Favours BMI>25 Favours BMI<25
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5  | CONCLUSION
Despite important differences between studies and relatively small 
sample	sizes,	data	consistently	suggest	raised	body	weight	is	a	risk	
factor	for	severe	disease	and	death	with	COVID-19.	This	is	particu-
larly	pronounced	in	older	age	groups	and	in	higher	BMI	ranges.	The	
increased	 risk	 of	 worse	 outcomes	 from	 SARS-CoV-2	 infection	 in	
people with overweight and obesity should be taken into account 
when considering individual and population risks and when decid-
ing on which groups to target with public health messaging and in-
creased prevention and detection measures.
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